Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07069426 · ClinicalTrials.gov registry record · NA
Muscle Response to Different Amounts of Dietary Protein During Leg Immobilization
A NA study of Muscle Disuse and Muscle Disuse Atrophy, sponsored by United States Army Research Institute of Environmental Medicine.
- Recruiting
- Registry status
- NA
- Development phase
- 28
- Enrollment target
- 1
- Study location
NCT07069426: Recruiting NA study of Muscle Disuse and Muscle Disuse Atrophy, sponsored by United States Army Research Institute of Environmental Medicine.
NCT07069426 is a NA study of Muscle Disuse and Muscle Disuse Atrophy that is actively recruiting participants, run by United States Army Research Institute of Environmental Medicine. The registered enrollment target is 28 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07069426, a NA study of Muscle Disuse and Muscle Disuse Atrophy, is actively recruiting participants, sponsored by United States Army Research Institute of Environmental Medicine.
- RECRUITING
- Registry status
- NA
- Development phase
- 28 participants
- Enrollment target
- 1
- Study location
Study Summary
Individuals who sustain musculoskeletal injuries (MSKI) can experience a rapid loss of muscle mass due to declines in muscle loading and activation that occur post-injury (i.e., disuse atrophy). Loss of muscle under these conditions is attributed to a persistent negative net muscle protein balance (muscle protein synthesis \[MPS\] \< muscle protein breakdown) that results, in part, from declines in postprandial MPS (i.e., anabolic resistance). Nutritional interventions that enhance postprandial MPS may be used to overcome disuse-induced anabolic resistance and preserve muscle mass to accelerate recovery and improve recovery outcomes. While supplemental protein has been explored as a potential countermeasure to disuse-induce anabolic resistance, the observed efficacy of such interventions has been mixed. Equivocal findings across studies may be attributed, in part, to an insufficient understanding of what constitutes an effective protein-based intervention. Importantly, no study to date has determined an optimal protein dose for overcoming disuse-induce anabolic resistance, or if there is a threshold for maximally stimulating postprandial MPS under disuse conditions. Therefore, the objective of this work is to determine rates of MPS at rest and in response to standard (20 g) or high (40 g) doses of whey protein during knee immobilization (DISUSE) compared with standard activity (ACTIVE)
Primary Outcome
Postabsorptive and postprandial muscle protein synthesis in response to 20 or 40 g of whey protein determined using 2H5-Phenylalanine stable isotope methodologies and expressed as fractional synthetic rate (FSR).
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT 20 grams protein
- DIETARY_SUPPLEMENT 40 grams protein
Study Locations (1)
Massachusetts
- US Army Research Institute of Environmental Medicine - Natick
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2025-09-01 |
| Est. Completion | 2026-09 |
| Phase | NA |
What NCT07069426 shows while recruiting
NCT07069426 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 28 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 2 conditions, with Muscle Disuse appearing as the primary indexed condition, and to 2 interventions - of which 20 grams protein is the first listed.
NCT07069426 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT07069426 about?
NCT07069426 is a clinical study titled "Muscle Response to Different Amounts of Dietary Protein During Leg Immobilization". Individuals who sustain musculoskeletal injuries (MSKI) can experience a rapid loss of muscle mass due to declines in muscle loading and activation that occur post-injury (i.e., disuse atrophy). Loss of muscle under these conditions is attributed to a persistent negative net muscle protein balance (...
What is the current status of trial NCT07069426?
This trial is currently recruiting. It is a NA study. The enrollment target is 28 participants. The study started on 2025-09-01. Estimated completion is 2026-09.
What conditions does trial NCT07069426 study?
This clinical trial studies the following conditions: Muscle Disuse, Muscle Disuse Atrophy.
What interventions are being tested in trial NCT07069426?
The interventions under investigation include: 20 grams protein (DIETARY_SUPPLEMENT), 40 grams protein (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT07069426?
This trial is sponsored by United States Army Research Institute of Environmental Medicine, which has 59 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07069426 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Muscle Disuse
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07069426's enrollment target sits among peer trials
28 1704th of 2000 higher than 293 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03471117 · 28 participants · Phase 4
Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients
- NCT03523975 · 28 participants · Phase 1
Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma
- NCT03608631 · 28 participants · Phase 1
iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation
- NCT03810651 · 28 participants · Early Phase 1
Pencil Beam Scanning in Patients With Renal Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI